We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ACTIVISTS: FDA PLEDGE TO CRACK DOWN ON UNAPPROVED DRUGS FALLS SHORT

ACTIVISTS: FDA PLEDGE TO CRACK DOWN ON UNAPPROVED DRUGS FALLS SHORT

June 9, 2006

The FDA's efforts to eliminate unapproved drugs from the market is more show than substance and seems to be part of an agency trend to tread lightly where industry is involved, an activist group says. But a former FDA official disagrees, arguing that the agency's announcement shows a new dedication to ending the practice.

The agency issued its guidance, Marketed Unapproved Drugs -- Compliance Policy Guide, with the intent of putting industry on notice that the FDA is serious about enforcing the regulations against companies that market drugs without getting agency approval. Unapproved drugs are a "significant and serious drug safety issue that must be addressed," Steven Galson, director of the agency's Center for Drug Evaluation and Research, said during a teleconference announcing the guide.

But this announcement is just "a show" that does not represent a real change in agency policy, Peter Lurie, the deputy director of Public Citizen's Health Research Group, told FDAnews. The group has been asking the FDA to change its policies on unapproved drugs since 1996 to no avail, he said.

The guidance only requests that companies voluntarily provide information on these drugs and submit new drug applications; it does not force them to act, Lurie said. The agency is being "naive" in thinking a mostly voluntary approach will be enough, he said. FDA is working under the "hope that a general fear [of possible enforcement] will cause the industry to do something."

But Marc Scheineson, a partner at the Washington, D.C., law firm Alston & Bird and former FDA associate commissioner for legislative affairs, responds that the agency is in fact "throwing down the gauntlet" to industry by finalizing this guidance. When the FDA first introduced the guidance in 2003, it faced tremendous political pressure from lobbyists representing unapproved manufacturers and some in Congress.

These opponents argued that the guidance was unnecessary. Finalizing the guidance and announcing its intent to enforce against some manufacturers is the FDA saying it "won't be intimidated politically," Scheineson added. But he acknowledged that the question remains whether the agency will aggressively enforce this policy. "Will they put their resources where their mouth is?" he asked.

The FDA also does not plan to recall any drugs that were on the shelves before the agency determines that they were being marketed illegally. This decision continues an agency trend of not going far enough to remove drugs from the market, even when there is a risk to public health, Lurie said. For example, the agency recently announced it would not recall supplies of Abbott Laboratories' attention deficit disorder drug Cylert, even though serious injuries have been associated with the drug. (http://www.fdanews.com/did/5_113/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

  • AI Software to Improve Echocardiogram Images Gets FDA Clearance

  • Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing